PHILADELPHIA, Jan. 26 /PRNewswire/ -- Liquent, Inc. today announced Omnicare Clinical Research has licensed LiquentConnect(R) - a hosted software as a service (SaaS) solution used to quickly and easily create, review, amend and submit regulatory dossiers. Omnicare Clinical Research is a leading Phase I to IV global contract research organization serving the biopharmaceutical and medical device industries.
“As portions of the industry shift toward SaaS, we are pleased to offer LiquentConnect, a SaaS solution publishing tool,” said Rick Riegel, Liquent’s Chief Executive Officer. “Liquent is committed to providing value-add solutions to our customers. LiquentConnect provides reliable, secure access to your dossiers from anywhere with an internet connection.”
“LiquentConnect provides our organization and our customers with project submission data that is safe and secure. Liquent provided us with a solution that is not only flexible, but one that we believe can expand to meet our needs and offer an efficient and cost-effective tool to address a variety of situations, from eCTD to NeeS to paper,” said Dr. Martine Dehlinger-Kremer, Vice President of Global Regulatory Affairs for Omnicare Clinical Research.
About Liquent, Inc.
Liquent regulatory solutions provide software and related regulatory and clinical services for the life sciences industry. These solutions and services help ensure clients meet the strict standards of regulatory authorities across the world helping them achieve quality, accuracy, and data integrity to deliver regulatory reports and submissions reliably and on time. For more information please visit, www.liquent.com.
CONTACT: Rick Riegel, CEO of Liquent, Inc., +1-215-328-4302
Web site: http://www.liquent.com/
